Telehealth platform Hims & Hers is on a mission to destigmatize issues common issues and its latest release was specifically designed to address hair loss in women. Topical Finasteride & Minoxidil Spray and Oral Spironolactone are a new pair of prescription products that cater to the one in three women (about 30 million women in the United States alone) who experience at some time in their lives.
While the Topical Finasteride & Minoxidil Spray pairs clinically proven ingredients in an easy-to-use, no-mess spot treatment, Oral Spironolactone is a once-a-day antiandrogen pill that reduces shedding and promotes regrowth.
Knowing that the experience can cause emotional distress, Hers created effective formulas with clinically proven ingredients that empower women to take control of their health and well-being.
What Makes This Trend Stand Out
- Hair Loss Treatments
- The popularity of D2C hair loss duos offers an opportunity for innovation in developing personalized and scientifically-proven hair loss treatments.
- Telehealth Platforms
- D2C hair loss duos highlight the potential for telehealth platforms as an accessible and convenient way for individuals to find treatments for common issues.
- Female Health Products
- The release of Hers' new prescription product pair offers an opportunity to develop more female-oriented health products that address common yet stigmatized issues.
Sectors Adopting This
- Pharmaceuticals
- As more D2C hair loss duos are released, the pharmaceutical industry can continue to innovate and develop new products using clinically-proven ingredients.
- Healthcare
- Telehealth platforms have the potential to disrupt the traditional healthcare industry by offering accessible and convenient solutions for common health issues, including hair loss.
- Beauty
- The popularity of hair loss treatments among both men and women highlights the potential for the beauty industry to expand its product offerings to include more solutions for hair loss and related issues.
